Form 4: Allakos Inc. Director Amy L. Ladd Reports Changes in Beneficial Ownership

Director Amy L. Ladd reports the cancellation of stock options due to the merger agreement between Allakos Inc., Concentra Biosciences, LLC, and Concentra Merger Sub III, Inc.

Summary

• On May 15, 2025, Amy L. Ladd, a director of Allakos Inc., reported changes in beneficial ownership of securities.
• The changes involve the cancellation of stock options due to the merger agreement dated April 1, 2025, between Allakos Inc., Concentra Biosciences, LLC, and Concentra Merger Sub III, Inc.
• Specifically, stock options with exercise prices of $4.34, $4.81, and $1.42 were cancelled without consideration.
• The cancelled options represented the right to buy 233,177, 86,762, and 41,000 shares of common stock, respectively.
• Following the reported transactions, the director's holdings of these specific stock options are now zero.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a merger, indicating a neutral sentiment. The cancellation of stock options is a procedural event tied to the merger agreement.

Industry Context

Mergers and acquisitions are common in the biotechnology industry, often leading to changes in stock option holdings for company directors and employees.

Stakeholder Impact

• Shareholders may be impacted by the merger, which is the underlying reason for the stock option cancellations.
• Employees holding similar stock options will also be affected by the cancellation.

Key Dates

Keywords

Allakos Inc., Amy L. Ladd, stock options, beneficial ownership, merger, Concentra Biosciences, Concentra Merger Sub III, director, securities, cancellation